Warm autoimmune haemolytic anaemia is a rare blood disorder where the immune system mistakenly attacks and destroys the body’s own red blood cells, leading to profound fatigue and a range of symptoms that can significantly impact daily life.

Understanding Treatment Goals and Approaches

When someone is diagnosed with warm autoimmune haemolytic anaemia, the focus of treatment shifts toward managing the immune system’s harmful activity and preserving enough red blood cells to keep the body functioning properly. This rare condition, where immunoglobulin G (IgG) antibodies mistakenly mark healthy red blood cells for destruction at normal body temperature, requires careful medical oversight and a treatment plan tailored to each person’s specific situation.^[1][2]

The main goals when treating this disease include stopping the destruction of red blood cells, increasing red blood cell count to safe levels, managing symptoms such as severe fatigue and jaundice, and addressing any underlying conditions that might be triggering the immune attack. Because red blood cells carry oxygen to every organ in the body, maintaining adequate levels becomes crucial for preventing serious complications like heart problems or organ damage.^[3]

Treatment decisions depend on several factors, including whether the condition is primary (occurring without a known cause) or secondary (linked to another disease such as lupus, rheumatoid arthritis, or blood cancers like lymphoma). The severity of the anaemia, how quickly symptoms developed, and how the patient responds to initial therapies all influence the treatment path. Some people experience a gradual onset of symptoms over weeks, while others face a rapid decline within days, requiring immediate intervention.^[1][4]

Medical societies and expert groups have established treatment guidelines based on decades of clinical experience and research, though it’s important to note that treatment approaches continue to evolve as new therapies emerge from ongoing clinical trials. The disease is highly manageable with proper medical care, but can be life-threatening if left untreated, making prompt diagnosis and treatment essential.^[6][9]

Standard Treatment Approaches

Corticosteroids represent the cornerstone of initial treatment for warm autoimmune haemolytic anaemia. These medications work by suppressing the immune system’s production of the harmful antibodies that attack red blood cells. Prednisone is the most commonly prescribed corticosteroid, typically started at high doses when the condition is first diagnosed. Medical guidelines recommend that approximately 70 to 85 percent of patients respond to corticosteroid therapy, though the response can vary considerably among individuals.^[6][9]

The typical treatment course begins with high-dose corticosteroids, often 60 milligrams of prednisone daily, continued for several weeks until laboratory markers improve and symptoms begin to resolve. Once the patient shows improvement—such as rising haemoglobin levels, decreasing jaundice, and reduced fatigue—doctors begin a slow tapering process. This gradual dose reduction usually takes place over six to twelve months, carefully monitoring the patient’s blood counts at each step. The slow taper is important because stopping corticosteroids too quickly can trigger a relapse of the disease.^[6][14]

Unfortunately, while most patients initially respond to corticosteroids, less than one-third maintain that response when the medication is reduced or stopped. Many people experience relapses, requiring either higher doses again or the addition of other therapies. Corticosteroids also come with significant side effects, particularly when used at high doses for extended periods. These can include weight gain, mood changes, increased risk of infections, elevated blood sugar levels, bone thinning (osteoporosis), high blood pressure, and changes in appearance such as facial swelling.^[9][14]

For patients who fail to respond adequately to corticosteroids, or who relapse when the dose is reduced, rituximab has emerged as an important second-line treatment option. Rituximab is a type of monoclonal antibody that targets and depletes B cells, the immune cells responsible for producing the harmful antibodies. Originally developed for treating blood cancers, rituximab has proven highly effective in autoimmune conditions including warm autoimmune haemolytic anaemia.^[6][9]

Clinical studies show that rituximab provides complete remission in approximately 75 to 90 percent of patients who have failed corticosteroid therapy. The medication is typically given as an intravenous infusion, usually at a dose of 375 milligrams per square meter of body surface area, administered weekly for four consecutive weeks. Some doctors use lower doses or different schedules with similar effectiveness. The benefits of rituximab can be long-lasting, with many patients maintaining remission for months or even years after treatment.^[8][9]

Recent clinical trial results have led some experts to consider using rituximab earlier in the treatment sequence, or even as first-line therapy in combination with corticosteroids. A phase 3 trial involving 64 patients found that after 12 months, 75 percent of patients treated with rituximab plus prednisolone showed satisfactory response, compared to only 36 percent of those given prednisolone alone. After 36 months, approximately 70 percent of patients who received rituximab remained in remission, compared to about 45 percent in the prednisolone-only group.^[8]

Splenectomy, the surgical removal of the spleen, represents another important treatment option, though it is increasingly being reserved for cases that don’t respond to medication. The spleen is the primary organ where antibody-coated red blood cells are destroyed by immune cells called macrophages. Removing the spleen can provide long-term remission in approximately two-thirds of patients, with some experiencing what may be considered a cure, meaning they require no further treatment for years.^[9][14]

The procedure can be performed either as traditional open surgery or using minimally invasive laparoscopic techniques. Recovery from laparoscopic splenectomy is typically faster, with most patients returning to normal activities within four to six weeks. However, splenectomy carries risks beyond those of surgery itself. The spleen plays an important role in fighting infections, particularly from certain bacteria. People without a spleen face a lifelong increased risk of serious infections, requiring vaccinations before surgery and sometimes preventive antibiotics afterward.^[15]

When rituximab and corticosteroids prove insufficient, doctors may turn to other immunosuppressive drugs that dampen the immune system’s activity through different mechanisms. These include azathioprine, cyclophosphamide, cyclosporin, and mycophenolate mofetil. More than 50 percent of patients who fail rituximab respond to these medications, though they can take several weeks or months to show their full effect. Each comes with its own side effect profile, including increased infection risk, nausea, liver problems, and in some cases, potential impacts on fertility or long-term cancer risk.^[6][9]

Intravenous immunoglobulin (IVIG) involves infusing concentrated antibodies from healthy donors into the patient. This treatment can be used in certain situations, though only a few patients with warm autoimmune haemolytic anaemia respond to it, and when they do, the benefit is usually temporary. IVIG is sometimes considered for patients who need rapid improvement but cannot undergo other therapies due to pregnancy, active infection, or other contraindications.^[6][8]

Another medication sometimes used is danazol, a synthetic hormone that can help reduce antibody production. Additionally, erythropoiesis-stimulating agents (ESAs) like darbepoetin alpha or epoetin alfa, which stimulate the bone marrow to produce more red blood cells, have shown benefit in some cases. These medications don’t stop the destruction of red blood cells, but they can help the body produce them faster, potentially keeping up with the rate of destruction.^[9][14]

Throughout treatment, patients are typically given folic acid supplementation. Active destruction of red blood cells consumes folate, a vitamin essential for producing new red blood cells. Without adequate folate, patients can develop a different type of anaemia called megaloblastic anaemia, compounding their problems. Prophylactic folic acid, usually 1 milligram daily, helps prevent this complication.^[8]

Blood transfusions are sometimes necessary when anaemia becomes severe enough to threaten the patient’s heart or other vital organs. However, transfusions are used cautiously in warm autoimmune haemolytic anaemia because the patient’s antibodies may also attack the transfused red blood cells. Finding compatible blood can be challenging, and transfused blood may be destroyed just as quickly as the patient’s own cells. When transfusions are needed, they are given slowly, often using the “least incompatible” blood available, and patients are monitored closely for reactions.^[8][10]

Emerging Therapies in Clinical Trials

The landscape of treatment for warm autoimmune haemolytic anaemia is evolving as researchers develop and test new targeted therapies in clinical trials. These investigations aim to provide more effective treatments with fewer side effects than traditional immunosuppressive medications, while also offering hope for patients who don’t respond to currently available options.

One promising drug currently being tested is fostamatinib, which works by inhibiting spleen tyrosine kinase (SYK), an enzyme involved in the signaling pathways that lead to red blood cell destruction by immune cells in the spleen. By blocking this enzyme, fostamatinib may reduce the destruction of antibody-coated red blood cells without broadly suppressing the entire immune system. Clinical trials have shown encouraging results, with patients maintaining stable haemoglobin levels on fostamatinib after failing multiple prior therapies. The drug is taken orally, typically at a dose of 150 milligrams twice daily, offering a convenient alternative to intravenous treatments.^[9][14]

Another investigational therapy showing promise is rilzabrutinib, which targets Bruton’s tyrosine kinase (BTK), another enzyme important in immune cell signaling. By inhibiting BTK, rilzabrutinib may reduce both the production of harmful antibodies and the destruction of red blood cells by immune cells. Early-phase clinical trials are evaluating this drug’s safety and efficacy in patients with warm autoimmune haemolytic anaemia, particularly those who have failed standard treatments.^[9][14]

A particularly innovative class of drugs being developed are FcRn inhibitors. These medications target the neonatal Fc receptor (FcRn), a protein that helps maintain antibody levels in the bloodstream by recycling them. By blocking FcRn, these drugs accelerate the breakdown and elimination of harmful IgG antibodies, including those attacking red blood cells. Several FcRn inhibitors are in various stages of clinical development for autoimmune conditions, with trials specifically enrolling patients with warm autoimmune haemolytic anaemia. This approach offers the potential to selectively reduce pathogenic antibodies while preserving other important immune functions.^[9][14]

Clinical trials for these new therapies typically progress through three phases. Phase I trials focus primarily on safety, testing the drug in a small number of participants to determine safe dosing ranges and identify side effects. Phase II trials expand to larger groups to assess whether the drug is effective at treating the disease while continuing to monitor safety. Phase III trials involve even larger patient populations and compare the new treatment directly against standard therapies to determine whether it offers superior or equivalent benefits with an acceptable safety profile.

Preliminary results from trials testing these novel agents have shown promising improvements in clinical parameters such as rising haemoglobin levels, reduced need for transfusions, decreased symptoms of fatigue and jaundice, and in some cases, improved quality of life scores. Safety profiles thus far appear acceptable, though longer follow-up is needed to fully understand potential side effects and long-term outcomes.

These clinical trials are being conducted at medical centers across multiple countries, including locations in the United States, Europe, and other regions worldwide. Patient eligibility for trials typically depends on factors such as previous treatments tried and failed, current disease severity, absence of certain other medical conditions, and willingness to comply with study requirements including regular monitoring visits and blood tests.

Most common treatment methods

• Corticosteroids
  • Prednisone, prednisolone, and methylprednisolone suppress immune system antibody production and are used as first-line therapy
  • Effective in 70-85% of patients initially, though less than one-third maintain response when tapered
  • Typically started at high doses (such as 60 mg prednisone daily) and slowly reduced over 6-12 months
  • Side effects include weight gain, mood changes, infection risk, elevated blood sugar, bone thinning, and high blood pressure
• Monoclonal antibody therapy
  • Rituximab targets and depletes B cells responsible for producing harmful antibodies
  • Provides complete remission in approximately 75-90% of patients who fail corticosteroids
  • Administered intravenously, typically 375 mg/m² weekly for four weeks
  • Increasingly used earlier in treatment, sometimes as first-line therapy combined with corticosteroids
  • Benefits can be long-lasting, with remissions extending months to years
• Splenectomy (surgical removal of spleen)
  • Removes primary site where antibody-coated red blood cells are destroyed
  • Provides long-term remission in approximately two-thirds of patients
  • Can be performed laparoscopically with 4-6 week recovery time
  • Results in lifelong increased infection risk requiring vaccinations and sometimes preventive antibiotics
  • Now typically reserved for cases not responding to medications
• Immunosuppressive drugs
  • Include azathioprine, cyclophosphamide, cyclosporin, and mycophenolate mofetil
  • Work through different mechanisms to dampen immune system activity
  • More than 50% of patients failing rituximab respond to these medications
  • May take several weeks to months to show full effect
  • Side effects include infection risk, nausea, liver problems, and potential fertility impacts
• Supportive therapies
  • Folic acid supplementation (typically 1 mg daily) prevents folate depletion from active red blood cell destruction
  • Erythropoiesis-stimulating agents (ESAs) like darbepoetin alpha stimulate bone marrow to produce more red blood cells
  • Intravenous immunoglobulin (IVIG) provides concentrated antibodies from healthy donors, though responses are usually temporary
  • Blood transfusions used cautiously when anaemia threatens vital organs, given slowly to minimize complications
• Investigational therapies in clinical trials
  • Fostamatinib inhibits spleen tyrosine kinase (SYK) to reduce red blood cell destruction, taken orally at 150 mg twice daily
  • Rilzabrutinib targets Bruton’s tyrosine kinase (BTK) to reduce antibody production and cell destruction
  • FcRn inhibitors accelerate elimination of harmful IgG antibodies by blocking neonatal Fc receptor
  • These novel agents show promising preliminary results in Phase I-III trials with acceptable safety profiles